Mobocertinib Use in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive mNSCLC

home / between-the-lines / mobocertinib-use-in-platinum-pretreated-patients-with-egfr-exon-20-insertion-positive-mnsclc

Expert oncologists review safety/efficacy data behind mobocertinib, a small molecule tyrosine kinase inhibitor, in patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer.